Other Information

Diomed Organisational Structure

Diomed Developments is an independent, privately owned company. The majority of the Group’s business is conducted in the UK. Diomed’s infrastructure comprises the research, development, manufacture, marketing and distribution of medicines and healthcare products primarily intended for the treatment of a variety of skin disorders, as well as other conditions which can be treated by applied medication. The Group consists of Dermal Laboratories, Diomed Pharmaceuticals, Diomed Herbals and Aeropak (Chemical Products).

Diomed's main operating sites are located at:

Hitchin, Hertfordshire – Head office functions, product development and marketing;
Kempston, Bedford – Warehousing & distribution, purchasing & supply, pilot production and ancillary offices;
Great Yarmouth, Norfolk – Manufacturing.

Diomed Supply Chain

Diomed operates with a vertically integrated Supply Chain which, in the main, encompasses the purchase of raw materials and packaging (starting materials), the manufacture of pharmaceuticals and the warehousing and distribution of the resultant finished products, primarily in the UK.

Modern Slavery Act 2015

“The Diomed Group is committed to ensuring that modern slavery is absent from its supply chain. All Staff are expected to report any potential or actual instances of slavery, and Senior Management are tasked to act on these reports.”

Michael Yarrow - Managing Director, Diomed Group

Due Diligence

Diomed will take steps to ensure slavery is absent from its supply chain, including, if necessary, the termination of the business relationship with any supplier unable or unwilling to support Diomed’s policy.

Diomed has a zero tolerance policy to slavery and an expectation that all suppliers and manufacturers in its supply chain will comply with its values.

Sourcing of starting materials is targeted on UK and European based suppliers, many of whom are suppliers of long standing to Diomed.

As a minimum, Diomed expects its ‘tier one’ suppliers to have in place suitable and effective anti-slavery policies. The written agreements with Diomed’s supplier base, such as Service Level Agreements and Technical Agreements, will include wording to this effect, where relevant.

Where the materials sourced are the subject of pharmaceutical industry licensing regulations, Diomed operates a robust audit regime with suppliers, and where the materials are defined as Active Pharmaceutical Ingredients, this audit regime also extends to the relevant manufacturers used by these suppliers. The audit process will include a section of questions pertinent to the detection and prevention of modern day slavery.

It is recognised that the initial supply of chemical ingredients and base materials that are ultimately converted into raw materials for use in Diomed’s products, may well start life in areas of the world that could be deemed to be at high risk of having slavery present. Diomed will review its supply base, using a risk based approach, to identify suppliers, or elements of its supply chain, in high risk geographical areas.